Home Cart Sign in  
Chemical Structure| 352458-37-8 Chemical Structure| 352458-37-8

Structure of Delafloxacin meglumine
CAS No.: 352458-37-8

Chemical Structure| 352458-37-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Delafloxacin meglumine is a fluoroquinolone antibiotic agent.

Synonyms: RX-3341 meglumine; ABT492 meglumine; Delafloxacin (meglumine)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Delafloxacin meglumine

CAS No. :352458-37-8
Formula : C25H29ClF3N5O9
M.W : 635.97
SMILES Code : O=C(C1=CN(C2=NC(N)=C(F)C=C2F)C3=C(C=C(F)C(N4CC(O)C4)=C3Cl)C1=O)O.O[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)CNC
Synonyms :
RX-3341 meglumine; ABT492 meglumine; Delafloxacin (meglumine)
MDL No. :MFCD26142921
InChI Key :AHJGUEMIZPMAMR-WZTVWXICSA-N
Pubchem ID :11578213

Safety of Delafloxacin meglumine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Escherichia coli CFT073 5 mg/ml 7 h Evaluate the bactericidal effect of Delafloxacin on stationary-phase UPEC CFT073. Results showed that approximately 99.99% of cells were killed after 7 h of treatment. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0028121
Escherichia coli EDL933 5 mg/ml 7 h Evaluate the bactericidal effect of Delafloxacin on stationary-phase EHEC EDL933. Results showed that approximately 99.9% of cells were killed after 7 h of treatment. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0028121
Escherichia coli MG1655 5 mg/ml 7 h Evaluate the bactericidal effect of Delafloxacin on stationary-phase E. coli MG1655. Results showed that approximately 99% of cells were killed after 7 h of treatment. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0028121
Haemophilus influenzae 0.001 and 0.004 μg/ml To test the antibacterial activity of delafloxacin against Haemophilus influenzae, results showed delafloxacin was the most potent agent, and its activity was unaffected by β-lactamase status. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5
Streptococcus pneumoniae 0.008 and 0.015 μg/ml To test the antibacterial activity of delafloxacin against Streptococcus pneumoniae, results showed delafloxacin was the most potent agent, exhibiting high activity against all S. pneumoniae isolates, including levofloxacin-resistant strains. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6381-5
Clinical Neisseria gonorrhoeae isolates 0.001 to 0.25 μg/ml Evaluated the in vitro activity of delafloxacin against N. gonorrhoeae, showing excellent activity against 117 strains including resistant isolates, with MIC50 and MIC90 of 0.06 μg/ml and 0.125 μg/ml, respectively. Antimicrob Agents Chemother. 2016 Apr 22;60(5):3106-11
sdrM::Tn mutant 0.32 μg/ml (MIC) To study the effect of sdrM deletion on DLX resistance. Results showed sdrM deletion led to a ~2-fold decrease in DLX MIC. Nat Commun. 2023 Jun 9;14(1):3402

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice PEP murine model of melioidosis Subcutaneous injection 30, 50, and 80 mg/kg body weight Four times daily for 21 days Evaluate the efficacy of delafloxacin in a murine model of melioidosis, results showed survival rates of 90% to 100% at doses of 50 and 80 mg/kg, with no detectable B. pseudomallei in the spleens of all treated cohorts. Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0073621
BALB/c mice Subcutaneous catheter infection model Intraperitoneal injection 40 mg/kg Delafloxacin twice daily, caspofungin once daily for 7 days To assess the efficacy of delafloxacin-caspofungin combination against S. aureus biofilms in vivo. Results demonstrated the combination significantly reduced bacterial load on catheters compared to delafloxacin alone, achieving complete sterilization for some strains. Nat Commun. 2016 Nov 3;7:13286.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.57mL

0.31mL

0.16mL

7.86mL

1.57mL

0.79mL

15.72mL

3.14mL

1.57mL

References

 

Historical Records

Categories